BerGenBio ASA

OSE:BGBIO.OL

0.16 (NOK) • At close November 27, 2023
Bedrijfsnaam BerGenBio ASA
Symbool BGBIO.OL
Munteenheid NOK
Prijs 0.152
Beurswaarde 398,320,548
Dividendpercentage 0%
52-weken bereik 0.075 - 9.8
Industrie Biotechnology
Sector Healthcare
CEO Mr. Martin Olin
Website https://www.bergenbio.com

An error occurred while fetching data.

Over BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II

Vergelijkbare Aandelen

Hofseth BioCare ASA logo

Hofseth BioCare ASA

HBC.OL

2.7 NOK

Nordhealth AS logo

Nordhealth AS

NORDH.OL

23.4 NOK

Carasent ASA logo

Carasent ASA

CARA.OL

11.5 NOK

Navamedic ASA logo

Navamedic ASA

NAVA.OL

36.8 NOK

Ultimovacs ASA logo

Ultimovacs ASA

ULTI.OL

107.4 NOK

Photocure ASA logo

Photocure ASA

PHO.OL

54 NOK

Financiële Gegevens

Cijfers zijn in miljoenen (NOK)

Cijfers zijn in miljoenen (NOK)